171 related articles for article (PubMed ID: 20033685)
1. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
Verburg FA; Hänscheid H; Biko J; Hategan MC; Lassmann M; Kreissl MC; Reiners C; Luster M
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):896-903. PubMed ID: 20033685
[TBL] [Abstract][Full Text] [Related]
2. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
3. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).
Bianchi L; Baroli A; Lomuscio G; Pedrazzini L; Pepe A; Pozzi L; Chiesa C
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):515-21. PubMed ID: 23358404
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
6. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
Lassmann M; Hänscheid H; Chiesa C; Hindorf C; Flux G; Luster M;
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1405-12. PubMed ID: 18491092
[TBL] [Abstract][Full Text] [Related]
7. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
8. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
[TBL] [Abstract][Full Text] [Related]
9. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
10. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.
Hänscheid H; Verburg FA; Biko J; Diessl S; Demidchik YE; Drozd V; Reiners C
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1296-302. PubMed ID: 21461735
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry in differentiated thyroid carcinoma (12-1402R).
Minguez P; Genolla J; Celeiro JJ; Fombellida JC
Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
[TBL] [Abstract][Full Text] [Related]
12. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
14. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
15. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
[TBL] [Abstract][Full Text] [Related]
16. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
17. Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma.
Verburg FA
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):253-257. PubMed ID: 31271272
[TBL] [Abstract][Full Text] [Related]
18. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
19. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]